Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
Julia Malicki, Amelia Baltes, Christopher R. Nicholas, David Horton, Paul R. Hutson, Randall Brown
Psychedelic Medicine December 1, 2023 DOI: 10.1089/psymed.2023.0012 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Clinical trial Peer reviewed |
|---|---|
| Population | People with opioid use disorder |
| Interventions | Psilocybin Buprenorphine |
| Topics | Addiction Psilocybin |
| Keywords | Buprenorphine Hallucinogen Psychotherapist Pharmacology |
| Citations | 7 |
| Registration | NCT05242029 |
| Key findings | Coadministration of psilocybin and buprenorphine was safely tolerated and did not show contraindicating effects on buprenorphine's effectiveness or psilocybin's subjective effects. |
Abstract
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall generalizability.clinicaltrials.gov ID: NCT05242029.
Comparable studies
Other non-randomized and open-label trials on psilocybin for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Psychiatrically healthy nicotine-dependent smokers | 2014 | Open-label pilot study | n = 15 |
| Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction Smokers | 2015 | Open-label pilot study | n = 15 |
| The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions Participants in a psilocybin-assisted treatment study for alcohol dependence | 2018 | Open-label pilot (proof-of-concept) study with qualitative content analysis | n = 17 |
| It’s time to take psilocybin seriously as a possible treatment for substance use disorders | 2016 | Pilot study | |
| Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study Treatment-seeking adults with severe alcohol use disorder | 2025 | Open-label, single-group study | n = 10 |